Why the study?
Despite available vaccines and vaccination programs in most endemic countries, Japanese encephalitis remains the leading recognized cause of viral encephalitis in Asia.
Expert recommendations were developed to sustain and expand Japanese encephalitis control through vaccination programs.
Answers are grounded in this paper and cite their sources.
Informs JE vaccination policies in endemic regions; extends prior control efforts with updated expert consensus.
Vaccines against Japanese encephalitis (JE) have been available for decades. Currently, most JE-endemic countries have vaccination programs for their at-risk populations. Even so, JE remains the leading recognized cause of viral encephalitis in Asia. In 2018, the U.S. Centers for Disease Control and Prevention and PATH co-convened a group of independent experts to review JE prevention and control successes, identify remaining scientific and operational issues that need to be addressed, discuss opportunities to further strengthen JE vaccination programs, and identify strategies and solutions to ensure sustainability of JE control during the next decade. This paper summarizes the key discussion points and recommendations to sustain and expand JE control.
No takes yet. Share an insight, caveat, or question.
Vannice et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: